Monday, March 09, 2020 12:24:30 AM
VANCOUVER, British Columbia, March 06, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it is exploring the potential of using NP-120 (Ifenprodil) as a novel treatment for COVID-19, also known as the coronavirus. A recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with H5N1 infected mice. H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate.
Based on this study, published by the American Society of Microbiology in mSystems in the December 2019 issue, the Company believes that Ifenprodil has the potential to be a front-line treatment for the most severe cases of coronavirus, and may also reduce morbidity in patients. Coronavirus currently has an overall predicted mortality rate of approximately 4%. Management’s belief that Ifenprodil is a possible treatment for COVID-19 is based on historic animal studies and not on human trials.
Despite the overall mortality rate of 4% based on current data, coronavirus-infected patients experience sometimes profound pulmonary complications including lung infiltrates, opacification, and risk of adult respiratory distress syndrome. Beyond systemic steroid therapy, clinicians have few agents with which to treat these patients and Ifenprodil may offer a new and efficacious treatment option that limits inflammatory infiltrates and the resulting fibrotic responses, as suggested in its earlier animal model studies.
Ifenprodil H5N1 Animal Study Background:
A genome wide RNAi interference approach to identify genes that aid in the recovery of cell viability after H5N1 infection, lead to the identification of the NMDA receptor antagonist Ifenprodil, which when tested in an animal model of H5N1 infection showed:
Markedly decreased leukocyte infiltration and lung injury scores in effected lungs
Significantly ameliorated edema infected mouse lung tissue
Significantly improved the survival of H5N1 infected mice by 40%
Study Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906739/
The company believes these findings could be relevant for reducing the lung-associated complications of coronavirus infection.
Algernon is preparing to apply for ethics approval in Australia for Ifenprodil, for its planned phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF) and chronic cough.
Recent BLOZF News
- Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • InvestorsHub NewsWire • 05/16/2024 12:13:10 PM
- Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • InvestorsHub NewsWire • 05/07/2024 12:51:17 PM
- Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • InvestorsHub NewsWire • 04/30/2024 12:53:40 PM
- Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • InvestorsHub NewsWire • 04/25/2024 12:52:01 PM
- Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • InvestorsHub NewsWire • 04/22/2024 12:49:29 PM
- Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • InvestorsHub NewsWire • 04/16/2024 12:52:49 PM
- Cannabix Quantifies Marijuana Breath Samples from Maryland Green Lab - Results Analyzed at North Louisiana Criminalistics Laboratory • InvestorsHub NewsWire • 01/18/2024 02:56:11 PM
- Shares Up on Patent Filing for Marijuana Breathalyzer • AllPennyStocks.com • 01/03/2024 07:00:00 PM
- Cannabix Technologies Files Patent for Proprietary Laboratory Drug Analysis Device • InvestorsHub NewsWire • 01/03/2024 02:30:21 PM
- Cannabix Technologies to Participate in Green Lab Held by Montgomery County Police Department (Maryland) • InvestorsHub NewsWire • 12/22/2023 01:46:36 PM
- Cannabix Completes Initial Electronics Testing on Contactless Alcohol Breathalyzer, Commences International Certification Plans • InvestorsHub NewsWire • 11/07/2023 02:09:46 PM
- Cannabix's MSBS Marijuana Breathalyzer Technology Advances Quantification of THC in Breath • InvestorsHub NewsWire • 10/03/2023 12:50:42 PM
- Cannabix Technologies Files Breath Sample Capture Patent and Detects Delta- 8 THC in Early Testing • InvestorsHub NewsWire • 08/04/2023 12:52:02 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM